User: Guest

MESENCHYMAL STEM CELLS (MSC)

Global Market Trajectory & Analytics

MCP-7815

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

2183

Interactions with Platform & by Email *

INTERACTIONS

393

Unique # Participated *

PARTICIPANTS

66

Responses Validated *

VALIDATIONS

31

* Login to view program details and full enterprise executive list.


  •  DATE

    AUGUST 2020

  •  TABLES

    108

  •  PAGES

    185

  •  EDITION

    19

  •  PRICE

    USD $5600


COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Mesenchymal Stem Cells (MSC) estimated at US$172.9 Million in the year 2020, is projected to reach a revised size of US$229 Million by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027. Human MSC, one of the segments analyzed in the report, is projected to record a 4.6% CAGR and reach US$94.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Mouse MSC segment is readjusted to a revised 4% CAGR for the next 7-year period.
The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$50.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$40.6 Million by the year 2027 trailing a CAGR of 3.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 3.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.
In the global Rat MSC segment, USA, Canada, Japan, China and Europe will drive the 3.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$27.7 Million in the year 2020 will reach a projected size of US$36.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$25.5 Million by the year 2027.We bring years of research experience to this 19th edition of our report. The 185-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, Cell Applications Inc.; Celprogen Inc.; Cyagen US Inc.; Genlantis Inc.; Lonza Group; Mesoblast Limited; MilliporeSigma; Neuromics; Orthofix International N.V.; PromoCell GmbH; R&D Systems Inc.; ScienCell Research Laboratories; Stemcell Technologies Inc.; Stemedica Cell Technologies Inc.; Thermo Fischer Scientific Inc.
» Type (Human MSC, Mouse MSC, Rat MSC, Other Types) » Application (Research Institutes, Hospitals, Other Applications)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL